DHR Danaher Corp.

$DHR Medtech market leader with a still lingering Covid hangover. As AI drug discovery accelerates, no better place to be.

$DHR Q3 adjusted EPS came in at 2.11 dollars vs 1.92 dollars consensus, and the FY guide went up to 8.57 to 8.62 dollars from 8.45 to 8.60. Reported revenue growth of 8.5% still leans on Masimo though, acquisitions added about 6.5 points of it. Core growth was 3.0%, 5.5% ex-respiratory, with Biotechnology core up 5.0% and Life Sciences up 4.5%.

the weird one this morning is a beat and raise getting sold. $DHR is ~6% lower premarket, 224.24 to ~211, after adjusted EPS of 2.11 vs 1.92 expected and a raised full year EPS guide to 8.57 to 8.62. the catch is growth: core revenue up just 3.0% (5.5% excluding respiratory testing, which fell to ~350 million dollars from ~500). Thermo Fisher is also lower, but I found no confirmed link, so call that unverified. premarket quotes.

Unusual OTM call flow on $DHR - $164K+ of the 10/23 $235 call - $82K+ of the 1/15 $250 call - $157K+ of the Jan. 2028 $290 call

$DHR opened down 3% this morning after a revenue miss and a CEO change. That opening print was the low of the day. It closed near 234, up about 4%. Selling in the first minute meant selling the exact bottom, right when the fear was loudest. A gap against you calls for a plan, not a panic click at 9:30 ET. Let the first 15 minute bar close and show you which way it wants to go. Gap down on your position: sell at the open or wait for the first bar?

$DHR - back to pre market lows possible…near term 210…way overvalued for its lackluster growth

$DHR: still no ruling on the fees in Hawkins. Lead counsel can ask up to a third of the $172.5M Danaher fund plus $850K in expenses, and the court has not decided. That cut shrinks the net pool. Claims closed. Open Class Actions.

$DHR Danaher reports Wednesday before the open. Consensus is 1.92 dollars EPS on 6.55 billion dollars in revenue, up 8.2% YoY (Zacks). Core organic growth is expected at just 2.5%, down from 3.0% a year ago. Diagnostics is modeled up 14.9% to 2.83 billion dollars, and Danaher closed the Masimo deal in June, which landed in that segment. Most of the headline growth is acquisition math, not underlying acceleration. Shares are up 8.9% over the past month into the print.

$DHR 🏥 Danaher Corporation's Masimo received FDA 510(k) clearance for an atrial fibrillation detection capability on its Radius VSM pulse oximetry platform, expanding the smartSET platform designed to help clinicians identify physiological changes earlier. Actionable market event

Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs $DHR $NVDA https://stocktwits.com/news/equity/markets/danaher-teams-up-with-nvidia-aims-to-bring-accelerated-computing-physical-ai-into-labs/cZxfZLDRBps

$DHR Our framework on Danaher Corporation yields a bullish stance, with 8 of 9 matrix cells positive and an average conviction of 3.75 out of 5. As shown in the chart attached, the only neutral reading is long-term technical momentum after an extended drawdown. Across the rest of the grid, evidence is constructive: a second-quarter earnings beat paired with raised guidance anchors the near term, while abating headwinds benefit the intermediate horizon. Sentiment aligns as well, highlighted by a twenty percent decline in short interest alongside steady institutional backing, with price holding above the 200-day moving average. We would change our mind if renewed headwinds impair free cash flow or if price breaks below the 200-day average. This reflects our read as of 21 Sep 2026—a dated snapshot, not a live call. (Disclosure: we're and this is our own research.)

$DHR: the math in Hawkins is front-loaded. Shares bought Jan to Oct 2022 carry $46.40 in alleged inflation per share, vs $8.71 for Jul to Oct 2023 buys. That gap drives the $1.13 average. Claims closed. Open Class Actions.

$DHR Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.11 up 11.64% YoY • Reported revenue of $6.55B up 8.28% YoY • Danaher expects its effective tax rate for the full year of 2026 to be approximately 17.0%, including anticipated discrete income tax benefits from excess tax deductions related to stock compensation programs.

$DHR: sold Danaher before Oct 20, 2022? That slice gets $0 in Hawkins. Recognized Loss only counts shares held through a corrective disclosure, and short sales count as zero too. Claims closed. Open Class Actions.